Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation

Collapse authors list.
Mallucci, Conor L ORCID: 0000-0002-5509-0547, Jenkinson, Michael D ORCID: 0000-0003-4587-2139, Conroy, EJ ORCID: 0000-0003-4858-727X, Hartley, John C, Brown, Michaela ORCID: 0000-0002-7772-271X, Dalton, Joanne ORCID: 0000-0003-1199-3047, Kearns, Tom, Moitt, Tracy ORCID: 0000-0002-5579-996X, Griffiths, Michael J, Culeddu, Giovanna et al (show 3 more authors) (2019) Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. Lancet, 394 (10208). pp. 1530-1539.

This is the latest version of this item.

Access the full-text of this item by clicking on the Open Access link.

	Text Supplementary Appendix_BASICS_2nd Revision_FINAL.docx - Author Accepted Manuscript Available under License : See the attached licence file. Download (807kB)
	Text Figures_BASICS_Lancet_2nd_REVISION.docx - Author Accepted Manuscript Available under License : See the attached licence file. Download (418kB)
	Text manuscript_BASICS_Lancet_2nd_REVISION (clean).docx - Author Accepted Manuscript Available under License : See the attached licence file. Download (111kB)

Official URL: https://www.thelancet.com/journals/lancet/article/...

Abstract

Background Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest neurosurgical procedures worldwide. Infection of the implanted shunt affects up to 15% of these patients, resulting in prolonged hospital treatment, multiple surgeries, and reduced cognition and quality of life. Our aim was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shunts at reducing infection. Methods In this parallel, multicentre, single-blind, randomised controlled trial, we included patients with hydrocephalus of any aetiology undergoing insertion of their first ventriculoperitoneal shunt irrespective of age at 21 regional adult and paediatric neurosurgery centres in the UK and Ireland. Patients were randomly assigned (1:1:1 in random permuted blocks of three or six) to receive standard shunts (standard shunt group), antibiotic-impregnated (0·15% clindamycin and 0·054% rifampicin; antibiotic shunt group), or silver-impregnated shunts (silver shunt group) through a randomisation sequence generated by an independent statistician. All patients and investigators who recorded and analysed the data were masked for group assignment, which was only disclosed to the neurosurgical staff at the time of operation. Participants receiving a shunt without evidence of infection at the time of insertion were followed up for at least 6 months and a maximum of 2 years. The primary outcome was time to shunt failure due the infection and was analysed with Fine and Gray survival regression models for competing risk by intention to treat. This trial is registered with ISRCTN 49474281. Findings Between June 26, 2013, and Oct 9, 2017, we assessed 3505 patients, of whom 1605 aged up to 91 years were randomly assigned to receive either a standard shunt (n=536), an antibiotic-impregnated shunt (n=538), or a silver shunt (n=531). 1594 had a shunt inserted without evidence of infection at the time of insertion (533 in the standard shunt group, 535 in the antibiotic shunt group, and 526 in the silver shunt group) and were followed up for a median of 22 months (IQR 10–24; 53 withdrew from follow-up). 32 (6%) of 533 evaluable patients in the standard shunt group had a shunt revision for infection, compared with 12 (2%) of 535 evaluable patients in the antibiotic shunt group (cause-specific hazard ratio [csHR] 0·38, 97·5% CI 0·18–0·80, p=0·0038) and 31 (6%) of 526 patients in the silver shunt group (0·99, 0·56–1·74, p=0·96). 135 (25%) patients in the standard shunt group, 127 (23%) in the antibiotic shunt group, and 134 (36%) in the silver shunt group had adverse events, which were not life-threatening and were mostly related to valve or catheter function. Interpretation The BASICS trial provides evidence to support the adoption of antibiotic shunts in UK patients who are having their first ventriculoperitoneal shunt insertion. This practice will benefit patients of all ages by reducing the risk and harm of shunt infection. Funding UK National Institute for Health Research Health Technology Assessment programme.

Item Type:	Article
Uncontrolled Keywords:	BASICS Study collaborators, Humans, Hydrocephalus, Silver, Anti-Bacterial Agents, Ventriculoperitoneal Shunt, Single-Blind Method, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Infant, Newborn, Cost-Benefit Analysis, Female, Male, Drug-Eluting Stents, Catheter-Related Infections, Young Adult
Depositing User:	Symplectic Admin
Date Deposited:	21 May 2020 09:05
Last Modified:	18 Jan 2023 23:52
DOI:	10.1016/S0140-6736(19)31603-4
Open Access URL:	https://doi.org/10.1016/S0140-6736(19)31603-4
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3086530